From heart to brain: cognitive potential of propranolol and diltiazem through cholinergic enhancement via butyrylcholinesterase inhibition
Open Access
- 13 November 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1694610
Abstract
Background: Butyrylcholinesterase (BChE) has emerged as a promising therapeutic target in the treatment of Alzheimer’s disease (AD), particularly in its later stages when acetylcholinesterase (AChE) activity declines. Drug repurposing offers a strategic approach to identify novel BChE inhibitors among existing FDA-approved compounds. Objective: This study aimed to evaluate the cholinesterase inhibitory potential of propranolol and diltiazem—two widely used cardiovascular drugs—through in silico modelling and in vitro and ex vivo enzyme-inhibition kinetic. Methods: Molecular docking was performed using AutoDock Vina to assess the binding affinity of propranolol and diltiazem to AChE and BChE. In vitro screening and inhibition were measured using a modified Ellman’s assay with human recombinant AChE and plasma-derived BChE. Ex-vivo IC 50 and K i values were determined through kinetic analyses in pooled plasma samples, and inhibition modes were characterized using nonlinear regression models. Results: Both propranolol and diltiazem selectively inhibited BChE, with minimal activity against AChE. At 100 μM, BChE inhibition exceeded 80% for both compounds, while AChE inhibition was limited to 18% (propranolol) and 2% (diltiazem). Propranolol exhibited a K i of 0.19 µM, comparable to the selective BChE inhibitor ethopropazine (K i = 0.15 µM), and acted as a competitive inhibitor. Diltiazem exhibited a higher K i of 2.3 µM. These effects were observed at concentrations within or near reported brain levels for propranolol, suggesting potential in vivo relevance. Conclusion: Propranolol and diltiazem demonstrate selective BChE inhibition, with propranolol showing potency comparable to established potent BChE inhibitors. Given their established safety profiles and CNS activity, these compounds represent promising candidates for repurposing in the treatment of AD and other cognitive disorders. Further in vivo studies are warranted to explore their therapeutic potential.Keywords
This publication has 69 references indexed in Scilit:
- Progress in Pharmacologic Management of Neuropsychiatric Syndromes in Neurodegenerative DisordersJAMA Neurology, 2024
- Proton pump inhibitors act with unprecedented potencies as inhibitors of the acetylcholine biosynthesizing enzyme—A plausible missing link for their association with incidence of dementiaAlzheimer's & Dementia, 2020
- Pharmacological Modulation of Vagal Nerve Activity in Cardiovascular DiseasesNeuroscience Bulletin, 2018
- Protective effect of a calcium channel blocker “diltiazem” on aluminum chloride-induced dementia in miceNaunyn-Schmiedeberg's Archives of Pharmacology, 2015
- Developing pharmacological therapies for Alzheimer diseaseCellular and Molecular Life Sciences, 2007
- Widely Spread Butyrylcholinesterase Can Hydrolyze Acetylcholine in the Normal and Alzheimer BrainNeurobiology of Disease, 2002
- Calcium Channel Antagonists Enhance Retention of Passive Avoidance and Maze Learning in MiceNeurobiology of Learning and Memory, 2001
- Distribution of butyrylcholinesterase in the human amygdala and hippocampal formationJournal of Comparative Neurology, 1998
- ?-blocker brain concentrations in manEuropean Journal of Clinical Pharmacology, 1985
- The Use of Diltiazem Hydrochloride in Cardiovascular DisordersPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 1982